NASDAQ:LIXT Lixte Biotechnology (LIXT) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free LIXT Stock Alerts $3.14 -0.12 (-3.68%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$3.10▼$3.2450-Day Range$2.20▼$3.7052-Week Range$1.58▼$9.50Volume6,124 shsAverage Volume435,641 shsMarket Capitalization$7.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lixte Biotechnology alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Lixte Biotechnology Stock (NASDAQ:LIXT)Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Read More LIXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIXT Stock News HeadlinesApril 25, 2024 | americanbankingnews.comLixte Biotechnology (NASDAQ:LIXT) Trading 1.9% Higher April 24, 2024 | theglobeandmail.comMixed Shelf Filing Gives Micro Cap Delayed BoostApril 29, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 29, 2024 | stockhouse.comNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESMarch 27, 2024 | theglobeandmail.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementMarch 27, 2024 | msn.comLixte stock soars on preclinical data for lead drug LB-100March 27, 2024 | marketwatch.comLixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer TreatmentMarch 21, 2024 | globenewswire.comLIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsApril 29, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…February 27, 2024 | globenewswire.comProfessor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer ResearchFebruary 26, 2024 | globenewswire.comLIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINovember 14, 2023 | finanznachrichten.deLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNovember 13, 2023 | finance.yahoo.comLIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNovember 9, 2023 | morningstar.comLixte Biotechnology Holdings Inc LIXTOctober 16, 2023 | finance.yahoo.comLIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationSeptember 26, 2023 | finance.yahoo.comLIXTE Appoints Bas van der Baan as President and Chief Executive OfficerAugust 27, 2023 | wsj.comLixte Biotechnology Holdings Inc. WtJuly 20, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 18, 2023 | benzinga.comWhy Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJuly 18, 2023 | msn.comLIXTE Biotechnology falls after company launches $3.5M registered direct offering of sharesJuly 18, 2023 | marketwatch.comLixte Bio Shares Tumble 31% After Pricing $3.5M Stock OfferingJuly 18, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 17, 2023 | marketwatch.comLixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment ResearchJuly 17, 2023 | msn.comWhat's Going On With Lixte Biotechnology (LIXT) Stock?July 17, 2023 | finance.yahoo.comPreclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyJune 23, 2023 | finance.yahoo.comLIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsJune 7, 2023 | finance.yahoo.comLIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue SarcomasSee More Headlines Receive LIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LIXT CUSIPN/A CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,202.60% Return on Assets-119.91% Debt Debt-to-Equity RatioN/A Current Ratio13.72 Quick Ratio13.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book14.27Miscellaneous Outstanding Shares2,250,000Free Float1,900,000Market Cap$7.07 million OptionableNot Optionable Beta-0.28 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Bastiaan van der Baan M.Sc. (Age 52)President, CEO & Chairman of the Board of Directors Comp: $172.78kMr. Robert Neal Weingarten (Age 72)VP & CFO Comp: $175kMr. Eric J. Forman J.D. (Age 45)VP & COO Comp: $200kDr. James S. Miser M.D. (Age 77)Chief Medical Officer Comp: $175kKey CompetitorsASLAN PharmaceuticalsNASDAQ:ASLNBiofronteraNASDAQ:BFRITFF PharmaceuticalsNASDAQ:TFFPBionomicsNASDAQ:BNOXUniverse PharmaceuticalsNYSE:UPCView All CompetitorsInsidersDer Baan Bastiaan Jeroen VanBought 10,000 shares on 10/3/2023Total: $28,000.00 ($2.80/share)View All Insider Transactions LIXT Stock Analysis - Frequently Asked Questions How have LIXT shares performed in 2024? Lixte Biotechnology's stock was trading at $2.35 on January 1st, 2024. Since then, LIXT shares have increased by 33.6% and is now trading at $3.14. View the best growth stocks for 2024 here. Are investors shorting Lixte Biotechnology? Lixte Biotechnology saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 82,700 shares, an increase of 395.2% from the March 31st total of 16,700 shares. Based on an average daily trading volume, of 547,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 4.6% of the company's stock are short sold. View Lixte Biotechnology's Short Interest. When is Lixte Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our LIXT earnings forecast. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.41) EPS for the quarter. When did Lixte Biotechnology's stock split? Lixte Biotechnology shares reverse split on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lixte Biotechnology IPO? Lixte Biotechnology (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO. How do I buy shares of Lixte Biotechnology? Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIXT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarningsGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
